Is Moderna Stock a Good Bet on Coronavirus Vaccines?

Moderna (NASDAQ: MRNA) is nearing the finish line in the coronavirus vaccine race. This biotech company has been among the leaders from the start. Back in March, it became the first company to launch a coronavirus vaccine trial in humans. Now, Moderna awaits a crucial step: word from the U.S. Food and Drug Administration (FDA). The FDA meets with an advisory committee on Dec. 17 to discuss whether to offer Emergency Use Authorization (EUA) to Moderna's investigational vaccine.

The company's path from early vaccine development to EUA request has been a smooth one. And that's reflected in the share price. Moderna shares have soared more than 700% this year. Now, the question is whether this stock still represents a good bet on coronavirus vaccines. Let's take a closer look.

Image source: Getty Images.

Continue reading

Source Fool.com